GREENFIELD, Ind, Nov. 25, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences.On Tuesday, December 3, Todd Young, executive vice president and CFO, will participate in a fireside chat at the Evercore ISI 7th Annual HealthCONx at 11:15 a.m. ET.On Thursday, December 5, Todd Young will participate in the Piper Sandler 36th Annual Healthcare Conference at 1:30 p.m. ET.Live audio webcasts will be available in the "E ...

NEW YORK, Nov. 24, 2024 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Elanco Animal Health Incorporated (NYSE: ELAN) between November 7, 2023 and June 26, 2024, both dates inclusive (the "Class Period"), of the important December 6, 2024 lead plaintiff deadline.So what: If you purchased Elanco securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem ...

NEW YORK, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

Group 1 - The Rosen Law Firm is reminding purchasers of Elanco Animal Health securities about a class action lawsuit with a lead plaintiff deadline of December 6, 2024 [1][3] - Investors who purchased Elanco securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][3] - The lawsuit alleges that Elanco made false and misleading statements regarding the safety and approval timelines of its products, Zenrelia and Credelio Quattro, which led to overstated business prospects [5] Group 2 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been recognized for its performance in securities class action settlements [4]

NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Nov. 22, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN).Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/?id=112959&from=4C ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Elanco Animal Health Incorporated due to allegations of misleading statements regarding product safety and approval timelines, which have led to significant investor losses [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $100,000 in Elanco between November 7, 2023, and June 26, 2024, to discuss their legal options [1]. - A federal securities class action has been filed against Elanco, with a deadline of December 6, 2024, for investors to seek the role of lead plaintiff [2][7]. - The complaint alleges that Elanco and its executives violated federal securities laws by making false statements about the safety of Zenrelia and the timelines for FDA approval of Zenrelia and Credelio Quattro [4]. Group 2: Product Safety and Approval Issues - Elanco's press release on June 27, 2024, indicated that Zenrelia would likely include a boxed warning on safety, which could slow product adoption and limit treatment days by approximately 25% [5]. - The company now expects FDA approval for Zenrelia in Q3 2024 and a commercial launch in Q4 2024, while Credelio Quattro is anticipated to receive FDA approval in Q4 2024 [5]. Group 3: Market Reaction - Following the announcement regarding the safety concerns and revised timelines, Elanco's stock price fell by $3.70 per share, or 20.59%, closing at $14.27 per share on June 27, 2024 [6].

NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) --  Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

Core Viewpoint - A lawsuit has been filed against Elanco Animal Health on behalf of investors who purchased its securities during the specified class period, indicating potential legal challenges for the company [1][3]. Company Overview - Elanco Animal Health develops products for both pets and farm animals, including Zenrelia, an oral Janus kinase inhibitor for canine dermatology, and Credelio Quattro, a parasiticide for dogs [3]. FDA Approval Timeline - In November 2023, Elanco set a timeline for U.S. FDA approval of Zenrelia and Credelio Quattro in the first half of 2024 [4]. - By May 2024, Elanco updated its timeline, expecting Zenrelia's approval and commercial launch in Q3 2024, and Credelio Quattro's approval in Q4 2024 [4]. - On June 27, 2024, Elanco indicated that Zenrelia would likely include a boxed safety warning, which could slow product adoption by approximately 25% and delay its approval to Q3 2024, with a potential commercial launch in Q4 2024 [5]. Stock Price Impact - Following the announcement regarding the FDA approval timelines and safety warnings, Elanco's stock price fell by $3.69 per share, or 20%, closing at $14.28 per share on June 27, 2024 [6].

NEW YORK, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...